GNOM vs. HELX

Last updated Jun 5, 2026

GNOM (Global X Genomics & Biotechnology ETF) and HELX (Franklin Genomic Advancements ETF) are both Health & Biotech Equities funds. GNOM is passively managed, while HELX is actively managed. Over the past 5 years, GNOM returned -9.59%/yr vs -3.93%/yr for HELX. Their correlation of 0.84 suggests significant overlap in exposure. Both charge a 0.50% expense ratio.

Performance

GNOM vs. HELX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Global X Genomics & Biotechnology ETF (GNOM) and Franklin Genomic Advancements ETF (HELX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GNOM achieves a 11.56% return, which is significantly higher than HELX's -1.55% return.

GNOM

• 1D: 3.47%
• 1M: 11.33%
• YTD: 11.56%
• 6M: 9.34%
• 1Y: 57.90%
• 3Y*: 0.45%
• 5Y*: -9.59%
• 10Y*: —

HELX

• 1D: 3.11%
• 1M: 5.81%
• YTD: -1.55%
• 6M: -4.90%
• 1Y: 33.84%
• 3Y*: 5.75%
• 5Y*: -3.93%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOM vs. HELX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
GNOM Global X Genomics & Biotechnology ETF	11.56%	18.65%	-15.99%	-8.63%	-36.27%	-15.93%	67.26%
HELX Franklin Genomic Advancements ETF	-1.55%	26.34%	-5.32%	1.14%	-37.89%	9.80%	85.05%

Correlation

The correlation between GNOM and HELX is 0.87, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.87
Correlation (3Y) Calculated over the trailing 3-year period	0.86
Correlation (5Y) Calculated over the trailing 5-year period	0.85
Correlation (All Time) Calculated using the full available price history since Feb 28, 2020	0.84

The correlation between GNOM and HELX has been stable across timeframes, ranging from 0.84 to 0.87 - a consistent structural relationship.

GNOM vs. HELX - Sectors Allocation Comparison

Sectors	GNOM	HELX
Healthcare	99.6%	96.5%
Technology	0.4%	0.9%
Basic Materials	-	2.7%
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	-
Industrials	-	-
Real Estate	-	-
Utilities	-	-

Return for Risk

GNOM vs. HELX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM

GNOM Risk / Return Rank: 62
GNOM Sharpe Ratio Rank: 67
GNOM Sortino Ratio Rank: 68
GNOM Omega Ratio Rank: 58
GNOM Calmar Ratio Rank: 66
GNOM Martin Ratio Rank: 54

HELX

HELX Risk / Return Rank: 42
HELX Sharpe Ratio Rank: 47
HELX Sortino Ratio Rank: 48
HELX Omega Ratio Rank: 44
HELX Calmar Ratio Rank: 39
HELX Martin Ratio Rank: 33

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOM vs. HELX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and Franklin Genomic Advancements ETF (HELX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GNOM	HELX	Difference
Sharpe ratio: Return per unit of total volatility	2.18	1.61	+0.57
Sortino ratio: Return per unit of downside risk	3.06	2.32	+0.74
Omega ratio: Gain probability vs. loss probability	1.35	1.28	+0.07
Calmar ratio: Return relative to maximum drawdown	3.20	1.89	+1.31
Martin ratio: Return relative to average drawdown	9.21	4.88	+4.33
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GNOM vs. HELX - Sharpe Ratio Comparison

The current GNOM Sharpe Ratio is 2.18, which is higher than the HELX Sharpe Ratio of 1.61. The chart below compares the historical Sharpe Ratios of GNOM and HELX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GNOM	HELX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.18	1.61	+0.57
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	-0.16	-0.12
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	0.25	-0.32

Drawdowns

GNOM vs. HELX - Drawdown Comparison

The maximum GNOM drawdown since its inception was -75.00%, which is greater than HELX's maximum drawdown of -58.75%. Use the drawdown chart below to compare losses from any high point for GNOM and HELX.

Drawdown Indicators

	GNOM	HELX	Difference
Max Drawdown Largest peak-to-trough decline	-75.00%	-58.75%	-16.25%
Max Drawdown (1Y) Largest decline over 1 year	-18.17%	-18.01%	-0.16%
Max Drawdown (3Y) Largest decline over 3 years	-46.47%	-29.48%	-16.99%
Max Drawdown (5Y) Largest decline over 5 years	-72.29%	-58.75%	-13.54%
Current Drawdown Current decline from peak	-53.90%	-38.22%	-15.68%
Average Drawdown Average peak-to-trough decline	-40.56%	-34.32%	-6.24%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.30%	6.95%	-0.65%

Volatility

GNOM vs. HELX - Volatility Comparison

Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 8.77% compared to Franklin Genomic Advancements ETF (HELX) at 7.45%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than HELX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GNOM	HELX	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.77%	7.45%	+1.32%
Volatility (6M) Calculated over the trailing 6-month period	19.72%	16.47%	+3.25%
Volatility (1Y) Calculated over the trailing 1-year period	26.66%	21.07%	+5.59%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.61%	24.15%	+9.46%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	34.19%	27.41%	+6.78%

GNOM vs. HELX - Expense Ratio Comparison

Both GNOM and HELX have an expense ratio of 0.50%.

Dividends

GNOM vs. HELX - Dividend Comparison

GNOM's dividend yield for the trailing twelve months is around 1.23%, more than HELX's 0.40% yield.

Position	TTM	2025	2024	2023	2022	2021	2020
GNOM Global X Genomics & Biotechnology ETF	1.23%	1.37%	0.00%	0.00%	0.00%	0.03%	0.14%
HELX Franklin Genomic Advancements ETF	0.40%	0.39%	0.00%	0.00%	0.00%	0.24%	0.12%

Frequently Asked Questions

Can I hold both GNOM and HELX in my portfolio?

GNOM and HELX have a correlation of 0.87, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GNOM or HELX?

GNOM has higher volatility (8.77%) compared to HELX (7.45%). In terms of maximum drawdown, GNOM dropped -75.00% vs HELX's -58.75%.

Which ETF is better, GNOM or HELX?

On 5-year performance, HELX leads with -3.93% vs -9.59% for GNOM. Both ETFs have the same 0.50% expense ratio. On volatility, HELX has been the lower-risk option at 7.45%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, GNOM or HELX?

Over the 5-year period, HELX has performed better with a -3.93% return vs -9.59%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, GNOM or HELX?

GNOM and HELX have the same expense ratio: 0.50% per year.

Which ETF pays a higher dividend yield, GNOM or HELX?

GNOM has the higher dividend yield at 1.23%, compared with 0.40% for HELX.

What is the main difference between GNOM and HELX?

They also come from different issuers: Global X and Franklin Templeton.

Which has better risk-adjusted returns?

GNOM currently has the higher Sharpe Ratio (2.18 vs 1.61), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.